Cost-effectiveness analysis of toripalimab combined with nab-paclitaxel as a first-line treatment for advanced TNBC in the US
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0320727 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Ping Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electro…. Hauptthemen laut MEDLINE: Paclitaxel, Albumins, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Key Research and Development Project of Science and Technology Department of Sichuan Province.
Abstract (Originalsprache)
Introduction
Initial immunotherapy outcomes with toripalimab suggest a potential paradigm shift in the treatment of advanced triple-negative breast cancer (TNBC), promising extended survival for patients. However, its cost-effectiveness in the treatment of TNBC within the US health care context remains to be determined.
Methods
A 5-year Markov model was developed using data from the TORCHLIGHT study to evaluate the cost-effectiveness of toripalimab plus nab-paclitaxel as a first-line therapy for metastatic or recurrent TNBC in the US. The model incorporated efficacy and safety data, literature-derived costs and utilities, and calculated ICERs. Sensitivity analyses were conducted to assess the impact of variable uncertainties on the outcomes.
Results
Toripalimab combined with nab-P chemotherapy for TNBC patients resulted in an additional 2.68 life years (LYs) and 1.72 quality-adjusted life years (QALYs), with an ICER of $593,750 per QALY. Sensitivity analyses indicated that the cost and survival utility of toripalimab significantly influence patient outcomes. At a $100,000/QALY WTP threshold, combination therapy was not cost-effective compared with nab-P alone.
Conclusions
Our analysis suggests that, from a US health care system perspective, toripalimab in combination with chemotherapy does not demonstrate a significant cost-effective advantage over nab-P chemotherapy as a first-line treatment for patients with TNBC at a WTP threshold of $100,000/QALY and has a limited impact on US health care policy and clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nursing, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
ORCID-Profile: Ping Chen
Förderung
- the Key Research and Development Project of Science and Technology Department of Sichuan Province
Zitieren
APA
Chen, P., Qiao, D., Xiao, L., Deng, G., Yang, Q., & Tian, R. (2025). Cost-effectiveness analysis of toripalimab combined with nab-paclitaxel as a first-line treatment for advanced TNBC in the US. PLOS ONE. https://doi.org/10.1371/journal.pone.0320727
Vancouver
Chen P, Qiao D, Xiao L, Deng G, Yang Q, Tian R. Cost-effectiveness analysis of toripalimab combined with nab-paclitaxel as a first-line treatment for advanced TNBC in the US. PLOS ONE. 2025. doi:10.1371/journal.pone.0320727
BibTeX
@article{Chen2025,
author = {Chen, Ping and Qiao, Dan and Xiao, Liping and Deng, Guiya and Yang, Qing and Tian, Rendi},
title = {Cost-effectiveness analysis of toripalimab combined with nab-paclitaxel as a first-line treatment for advanced TNBC in the US},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0320727}
}
EUVIMED